Figure 3
From: Response to imatinib as a function of target kinase expression in recurrent glioblastoma
MRI slides of patient with major response. T1 weighted, contrast enhanced MRT. A: Horizontal: before start of imatinib: with a left frontal lesion with contrast enhancement. B: Horizontal: 3 months after start of imatinib, contrast enhancement of the lesion is not longer visible. C: coronal, before start of imatinib with the contrast enhancing lesion near the ventricle. D: coronal, 3 months after start of imatinib: no contrast enhancing lesion visible. The best fitted sections were selected for this image, as the head positioning and bending of the neck were not exactly similar in both examinations.